“Tutalthromycin second gen”的搜索结果

7 个项目

每页

设置降序顺序
  1. CCK2R Ligand-Linker Conjugates 1

    Catalog No. A18411
    Quick View
    ligand-linker conjugate
    CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker. 了解更多
  2. PROTAC ER Degrader-3

    Catalog No. A18519
    Quick View
    PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab). 了解更多
  3. PROTAC ERRα Degrader-2

    Catalog No. A18904
    Quick View
    ERRa degrader
    PROTAC ERRalpha Degrader-2 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRalpha Degrader-2 is an estrogen-related receptor alpha (ERRa) degrader. 了解更多
  4. PROTAC ERRα Degrader-1

    Catalog No. A18910
    Quick View
    ERRα Degrader
    PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an estrogen-related receptor alpha (ERRa) degrader. 了解更多
  5. PROTAC ERRα ligand 2

    Catalog No. A18939
    Quick View
    ERRα inverse agonist
    PROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist with an IC50 of 5.67 nM. PROTAC ERRα ligand 2 (IC50=5.67 nM) displays a ~11-fold improved potency than XCT790 (IC50=61.3 nM). 了解更多
  6. ERD-308

    Catalog No. A18446
    Quick View
    ER PROTAC degrader
    ERD-308 is a highly potent PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. 了解更多
    • 最新产品

    MD-224

    Catalog No. A18712
    Quick View
    MDM2 degrader
    MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (MDM2) degrader based on the proteolysistargeting chimera (PROTAC) concept. MD-224 has the potential to be a new class of anticancer agent. 了解更多

7 个项目

每页

设置降序顺序
Rewards